Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Why Vertex’s and CRISPR Therapeutics’ Stocks Are Rallying

June 7, 2019 0

Vertex and CRISPR Therapeutics While some groups are doubting the gene editing capability of CRISPR gene …

Gilead Sciences: Improving the Safety and Efficacy of Yescarta® CAR T

June 6, 2019 0

AT ASCO Gilead Sciences and Yescarta® By Acquiring Kite Pharma Gilead Sciences(GILD) gained Kite’s CAR T technology …

bluebird bio Announces a European Conditional Approval of Its Gene Therapy ZYNTEGLO™ for Transfusion-Dependent β-Thalassemia

June 4, 2019 0

Zynteglo™ from bluebird bio Gets European Conditional Approval European marketing authorization for Zynteglo follows the fastest …

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

June 4, 2019 0

What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is …

Cara Therapeutics: More Positive Results from the Korsuva Product Trial for Hemodialysis Patients’ Pruritis

May 30, 2019 0

Positive Results from Korsuva for Pruritis Cara Therapeutics Postive Results from Korsuva Trial On May 29, …

Recent News from Incyte, Merck and Nektar

May 29, 2019 0

Incyte's FDA Approval Based on encouraging data from the REACH1 trial the FDA approved a label …

Genomes, Genes and Gene Therapies

May 28, 2019 0

Prohost Letter #431 Genomes, Genes and Gene Therapies In this issue of the Prohost Letter we …

Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

May 24, 2019 0

Amgen, the Biotech King Amgen (AMGN), the biotech king, wanted to buy all of the Denmark …

Vertex: Good News and Good Decisions

May 23, 2019 0

Vertex’s Good News Vertex and Kymera Therapeutics Collaboration Last week Vertex Pharmaceuticals (VRTX) and Kymera Therapeutics entered …

Array BioPharma: Great News and a Learning Experience

May 21, 2019 0

Great News for Array BioPharma Array BioPharma (ARRY) announced positive results from the interim analysis of …

The Medicines Company: Are Inclisiran’s Clinical Trial Results Impressive?

May 21, 2019 0

The Medicines Company Are Inclisiran's Clinical Trial Results Impressive? Our answer is YES. The trial results …

Another Late-Stage Firm with Impressive Technology and Promising Products

May 16, 2019 0

About Iovance Biotherapeutics Iovance Biotherapeutics (IOVA) is a late-stage biotechnology company developing novel cancer immunotherapies based on …

Advaxis: Why This Small Firm’s Stock Outperformed on a Negative Market Day

May 15, 2019 0

Advaxis Outperformed on a Negative Market Day ADXS Outperformed Advaxis’ (ADXS) stock rallied today as the …

Regeneron: Why the FDA Approval of EYLEA for Diabetic Retinopathy is Extremely Important.

May 14, 2019 0

The FDA Approval of Regeneron's EYLEA Is Important The PANORAMA Trial of EYLEA for Diabetic Retinopathy …

Exelixis’ and Daiichi Sankyo’s Novel Antihypertensive Drug Minnebro® Hits the Japanese Market

May 13, 2019 0

Exelixis and Daiichi Sankyo launched their novel anitihypertension product Minnebro® in Japan Exelixis (EXEL) and Daiichi Sankyo (

Will the Bear Escape Tonight from the Market? Regeneron and Severe Asthma Patients Good News

May 9, 2019 0

The Stock Market The Confused and Confusing Stock Market The stock market is confused and confusing. …

A Firm That Defied the Fierce Unwarranted Bear Market Day

May 7, 2019 0

Why GW Pharmaceuticals Survived the Bear Market Day The DOW Today Sinking for disputed and unfathomed …

Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last Resort Multiple Myeloma Treatment

May 3, 2019 0

A Great Day for Bluebird bio and Celgene Read the Clinical Trial Results for Myeloma What …

Vertex Has Good News and Exelixis Is Reinforcing Its Outperformance

May 2, 2019 0

Vertex Pharmaceuticals' Product Kalydeco for CF in Young Children Good news for Vertex (VRTX) product Kalydeco® (ivacaftor) is …

The FDA Approval of Regeneron/Sanofi Praluent Is A Big Deal. Will the FDA Approve Nabriva Therapeutics’ Antibiotic Contepo Today?

April 30, 2019 0

Praluent's Approval Is a Big Deal The approval of the Regeneron / Sanofi supplemental biological license …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd